Skip to main content
Erschienen in: CNS Drugs 7/2019

01.07.2019 | Original Research Article

Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study

verfasst von: Bruno Agustini, Mohammadreza Mohebbi, Robyn L. Woods, John J. McNeil, Mark R. Nelson, Raj C. Shah, Anne M. Murray, Michael E. Ernst, Christopher M. Reid, Andrew Tonkin, Jessica E. Lockery, Michael Berk, the ASPREE Investigator Group

Erschienen in: CNS Drugs | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Statin use has been frequently associated with depressive symptoms in an older population. However, the nature of this association is uncertain in the literature. In this study, we aimed to investigate the association of statin intake and the prevalence of depressive symptoms in healthy community-dwelling older adults living in Australia and the USA.

Methods

We analysed baseline data from 19,114 participants, over 70 years of age (over 65 years of age, if from an ethnic minority). The association of self-reported statin use and prevalence of depressive symptoms, as measured by a validated depression scale [Center for Epidemiological Studies Depression Scale (CES-D 10)], was determined using logistic regression models. Multivariable logistic models were implemented to account for important demographics and other lifestyle and socioeconomic factors, such as sex, age, living status, education and smoking history.

Results

A total of 5987 individuals were statin users. Of those, 633 (10.6%) had depressive symptoms (CES-D 10 cut-off ≥ 8), compared with 1246 (9.5%) of the non-statin users. In the unadjusted model, statin use was associated with an increase in prevalence of depressive symptoms (odds ratio 1.13, confidence interval 1.02–1.25, p = 0.02). However, after adjusting for important demographic and socioeconomic factors, the use of statins was not significantly associated with depressive symptoms (odds ratio 1.09, confidence interval 0.98–1.20, p = 0.11). In secondary analyses, only simvastatin was marginally associated with an increased prevalence of depressive symptoms. Statins were associated with a decreased prevalence of depressive symptoms in individuals with severe obesity (body mass index > 35 kg/m2) and an increased prevalence in participants between 75 and 84 years of age.

Conclusion

This study in a large community-dwelling older population did not show any association of statins with late-life depressive symptoms, after accounting for important socioeconomic and demographic factors. Confounding by indication is an important issue to be addressed in future pharmacoepidemiologic studies of statins.
Literatur
1.
Zurück zum Zitat Arokiasamy P, et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? BMC Med. 2015;13(1):1–16.CrossRef Arokiasamy P, et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? BMC Med. 2015;13(1):1–16.CrossRef
2.
Zurück zum Zitat World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017. p. 1–24. World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017. p. 1–24.
4.
Zurück zum Zitat Bakunina N, Pariante CM, Zunszain PA. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology. 2015;144(3):365–73.CrossRefPubMedPubMedCentral Bakunina N, Pariante CM, Zunszain PA. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology. 2015;144(3):365–73.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat You H, Lu W, Zhao S, Hu Z, Zhang J. The relationship between statins and depression: a review of the literature. Expert Opin Pharmacother. 2013;14(11):1467–76.CrossRefPubMed You H, Lu W, Zhao S, Hu Z, Zhang J. The relationship between statins and depression: a review of the literature. Expert Opin Pharmacother. 2013;14(11):1467–76.CrossRefPubMed
6.
Zurück zum Zitat Williams LJ, et al. Statin and aspirin use and the risk of mood disorders among men. Int J Neuropsychopharmacol. 2016;19(6):1–4. Williams LJ, et al. Statin and aspirin use and the risk of mood disorders among men. Int J Neuropsychopharmacol. 2016;19(6):1–4.
7.
Zurück zum Zitat Salagre E, Fernandes BS, Dodd S, Brownstein DJ, Berk M. Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord. 2016;200:235–42.CrossRefPubMed Salagre E, Fernandes BS, Dodd S, Brownstein DJ, Berk M. Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord. 2016;200:235–42.CrossRefPubMed
8.
Zurück zum Zitat Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X. Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry. 2014;14:438.CrossRef Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X. Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry. 2014;14:438.CrossRef
9.
Zurück zum Zitat Mandas A, et al. Cognitive decline and depressive symptoms in late-life are associated with statin use: evidence from a population-based study of Sardinian old people living in their own home. Neurol Res. 2014;36(3):247–54.CrossRefPubMed Mandas A, et al. Cognitive decline and depressive symptoms in late-life are associated with statin use: evidence from a population-based study of Sardinian old people living in their own home. Neurol Res. 2014;36(3):247–54.CrossRefPubMed
10.
Zurück zum Zitat Tuccori M, et al. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs. 2014;28(3):249–72.CrossRefPubMed Tuccori M, et al. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs. 2014;28(3):249–72.CrossRefPubMed
11.
Zurück zum Zitat Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.CrossRefPubMed Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.CrossRefPubMed
12.
Zurück zum Zitat Dave CV, Winterstein AG, Park H, Cook RL, Hartzema AG. Comparative risk of lipophilic and hydrophilic statins on incident depression: a retrospective cohort study. J Affect Disord. 2018;238:542–6.CrossRefPubMed Dave CV, Winterstein AG, Park H, Cook RL, Hartzema AG. Comparative risk of lipophilic and hydrophilic statins on incident depression: a retrospective cohort study. J Affect Disord. 2018;238:542–6.CrossRefPubMed
13.
Zurück zum Zitat Glaus J, et al. Aspirin and statin use and the subsequent development of depression in men and women: results from a longitudinal population-based study. J Affect Disord. 2015;182:126–31.CrossRefPubMed Glaus J, et al. Aspirin and statin use and the subsequent development of depression in men and women: results from a longitudinal population-based study. J Affect Disord. 2015;182:126–31.CrossRefPubMed
14.
Zurück zum Zitat Bulbulia R, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378(9808):2013–20.CrossRef Bulbulia R, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378(9808):2013–20.CrossRef
15.
Zurück zum Zitat Collins R, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.CrossRefPubMed Collins R, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.CrossRefPubMed
16.
Zurück zum Zitat Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71(1):85–94.CrossRefPubMed Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71(1):85–94.CrossRefPubMed
17.
Zurück zum Zitat Ruscica M, Macchi C, Pavanello C, Corsini A, Sahebkar A, Sirtori CR. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018;50:33–40.CrossRefPubMed Ruscica M, Macchi C, Pavanello C, Corsini A, Sahebkar A, Sirtori CR. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018;50:33–40.CrossRefPubMed
18.
Zurück zum Zitat Waters DD. Meta-analyses of statin trials: clear benefit for primary prevention in the elderly. J Am Coll Cardiol. 2013;62(22):2100–1.CrossRefPubMed Waters DD. Meta-analyses of statin trials: clear benefit for primary prevention in the elderly. J Am Coll Cardiol. 2013;62(22):2100–1.CrossRefPubMed
19.
Zurück zum Zitat Ridker PM. Should aspirin be used for primary prevention in the post-statin era? N Engl J Med. 2018;379(16):1572–4.CrossRefPubMed Ridker PM. Should aspirin be used for primary prevention in the post-statin era? N Engl J Med. 2018;379(16):1572–4.CrossRefPubMed
20.
21.
Zurück zum Zitat McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509–18.CrossRefPubMedPubMedCentral McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509–18.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Grimm R, et al. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36(2):555–64.CrossRef Grimm R, et al. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36(2):555–64.CrossRef
23.
Zurück zum Zitat Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1993;10(2):77–84.CrossRef Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1993;10(2):77–84.CrossRef
24.
Zurück zum Zitat Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): a systematic review with meta-analysis. PLoS One. 2016;11(5):1–17.CrossRef Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): a systematic review with meta-analysis. PLoS One. 2016;11(5):1–17.CrossRef
25.
Zurück zum Zitat Mohebbi M, et al. Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults. Gen Hosp Psychiatry. 2018;51:118–25.CrossRefPubMed Mohebbi M, et al. Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults. Gen Hosp Psychiatry. 2018;51:118–25.CrossRefPubMed
26.
Zurück zum Zitat Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult. Arch Intern Med. 1999;159:1701–4.CrossRefPubMed Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult. Arch Intern Med. 1999;159:1701–4.CrossRefPubMed
27.
Zurück zum Zitat Cheng ST, Chan ACM. The Center for Epidemiologic Studies Depression Scale in older Chinese: thresholds for long and short forms. Int J Geriatr Psychiatry. 2005;20(5):465–70.CrossRefPubMed Cheng ST, Chan ACM. The Center for Epidemiologic Studies Depression Scale in older Chinese: thresholds for long and short forms. Int J Geriatr Psychiatry. 2005;20(5):465–70.CrossRefPubMed
28.
Zurück zum Zitat Alberti KGM, Zimmet P, Shaw J. The IDF consensus worldwide definition of the metabolic syndrome. Brussels Int Diabetes Fed. 2006;23(5):469–80. Alberti KGM, Zimmet P, Shaw J. The IDF consensus worldwide definition of the metabolic syndrome. Brussels Int Diabetes Fed. 2006;23(5):469–80.
30.
Zurück zum Zitat Delgado I, et al. Depressive symptoms in obesity: relative contribution of low-grade inflammation and metabolic health. Psychoneuroendocrinology. 2018;91:55–61.CrossRefPubMed Delgado I, et al. Depressive symptoms in obesity: relative contribution of low-grade inflammation and metabolic health. Psychoneuroendocrinology. 2018;91:55–61.CrossRefPubMed
31.
Zurück zum Zitat Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. Am J Hypertens. 2015;28(11):1295–302.CrossRefPubMedPubMedCentral Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. Am J Hypertens. 2015;28(11):1295–302.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat De Jonge P, Roy JF, Saz P, Marcos G, Lobo A. Prevalent and incident depression in community-dwelling elderly persons with diabetes mellitus: results from the ZARADEMP project. Diabetologia. 2006;49(11):2627–33.CrossRefPubMed De Jonge P, Roy JF, Saz P, Marcos G, Lobo A. Prevalent and incident depression in community-dwelling elderly persons with diabetes mellitus: results from the ZARADEMP project. Diabetologia. 2006;49(11):2627–33.CrossRefPubMed
33.
Zurück zum Zitat Bagherniya M, et al. Metabolic syndrome and its components are related to psychological disorders: a population based study. Diabetes Metab Syndr Clin Res Rev. 2017;11:S561–6.CrossRef Bagherniya M, et al. Metabolic syndrome and its components are related to psychological disorders: a population based study. Diabetes Metab Syndr Clin Res Rev. 2017;11:S561–6.CrossRef
34.
Zurück zum Zitat Mulvahill JS, et al. Effect of metabolic syndrome on late-life depression: associations with disease severity and treatment resistance. J Am Geriatr Soc. 2017;65(12):2651–8.CrossRefPubMedPubMedCentral Mulvahill JS, et al. Effect of metabolic syndrome on late-life depression: associations with disease severity and treatment resistance. J Am Geriatr Soc. 2017;65(12):2651–8.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA. 2018;319(22):2289.CrossRefPubMedPubMedCentral Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA. 2018;319(22):2289.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Agustini B, Berk M. Medications with depression as an adverse effect. JAMA. 2018;320(17):1815.CrossRefPubMed Agustini B, Berk M. Medications with depression as an adverse effect. JAMA. 2018;320(17):1815.CrossRefPubMed
37.
Zurück zum Zitat Friis RH, Sellers TA. Experimental study designs. Epidemiol Public Health Pract. 2009;275(6):327–60. Friis RH, Sellers TA. Experimental study designs. Epidemiol Public Health Pract. 2009;275(6):327–60.
38.
Zurück zum Zitat Köhler-Forsberg O, Gasse C, Petersen L, Nierenberg AA, Mors O, Østergaard SD. Statin treatment and the risk of depression. J Affect Disord. 2019;246:706–15.CrossRefPubMed Köhler-Forsberg O, Gasse C, Petersen L, Nierenberg AA, Mors O, Østergaard SD. Statin treatment and the risk of depression. J Affect Disord. 2019;246:706–15.CrossRefPubMed
39.
Zurück zum Zitat Mansi I, Frei CR, Pugh MJ, Mortensen EM. Psychologic disorders and statin use: a propensity score-matched analysis. Pharmacotherapy. 2013;33(6):615–26.CrossRefPubMedPubMedCentral Mansi I, Frei CR, Pugh MJ, Mortensen EM. Psychologic disorders and statin use: a propensity score-matched analysis. Pharmacotherapy. 2013;33(6):615–26.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Schaakxs R, Comijs HC, Lamers F, Kok RM, Beekman ATF, Penninx BWJH. Articles associations between age and the course of major depressive disorder: a 2-year longitudinal cohort study. Lancet Psychiatry. 2018;366(18):1–10. Schaakxs R, Comijs HC, Lamers F, Kok RM, Beekman ATF, Penninx BWJH. Articles associations between age and the course of major depressive disorder: a 2-year longitudinal cohort study. Lancet Psychiatry. 2018;366(18):1–10.
41.
Zurück zum Zitat Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18(9):963–74.CrossRefPubMedPubMedCentral Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18(9):963–74.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Geerlings MI, Gerritsen L. Late-life depression, hippocampal volumes, and hypothalamic-pituitary-adrenal axis regulation: a systematic review and meta-analysis. Biol Psychiatry. 2017;82(5):339–50.CrossRefPubMed Geerlings MI, Gerritsen L. Late-life depression, hippocampal volumes, and hypothalamic-pituitary-adrenal axis regulation: a systematic review and meta-analysis. Biol Psychiatry. 2017;82(5):339–50.CrossRefPubMed
43.
Zurück zum Zitat Liang Feng TPN, Yap KB, Kua E. Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiol Drug Saf. 2010;19:942–8.CrossRefPubMed Liang Feng TPN, Yap KB, Kua E. Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiol Drug Saf. 2010;19:942–8.CrossRefPubMed
44.
Zurück zum Zitat Bornstein SR, Schuppenies A, Wong M-L, Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Mol Psychiatry. 2006;11(10):892–902.CrossRefPubMed Bornstein SR, Schuppenies A, Wong M-L, Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Mol Psychiatry. 2006;11(10):892–902.CrossRefPubMed
45.
Zurück zum Zitat Raison CL, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry. 2013;70(1):31–41.CrossRefPubMedPubMedCentral Raison CL, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry. 2013;70(1):31–41.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Köhler O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects. JAMA Psychiatry. 2014;71(12):1381–91.CrossRefPubMed Köhler O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects. JAMA Psychiatry. 2014;71(12):1381–91.CrossRefPubMed
47.
Zurück zum Zitat McFarland AJ, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci. 2014;15(11):20607–37.CrossRefPubMedPubMedCentral McFarland AJ, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci. 2014;15(11):20607–37.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Davison KM, Kaplan BJ. Lipophilic statin use and suicidal ideation in a sample of adults with mood disorders. Crisis. 2014;35(4):278–82.CrossRefPubMed Davison KM, Kaplan BJ. Lipophilic statin use and suicidal ideation in a sample of adults with mood disorders. Crisis. 2014;35(4):278–82.CrossRefPubMed
49.
Zurück zum Zitat Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of depression in patients with concomitant cardiac disease. Prog Cardiovasc Dis. 2016;58(5):514–28.CrossRefPubMed Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of depression in patients with concomitant cardiac disease. Prog Cardiovasc Dis. 2016;58(5):514–28.CrossRefPubMed
Metadaten
Titel
Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study
verfasst von
Bruno Agustini
Mohammadreza Mohebbi
Robyn L. Woods
John J. McNeil
Mark R. Nelson
Raj C. Shah
Anne M. Murray
Michael E. Ernst
Christopher M. Reid
Andrew Tonkin
Jessica E. Lockery
Michael Berk
the ASPREE Investigator Group
Publikationsdatum
01.07.2019
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 7/2019
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-019-00633-3

Weitere Artikel der Ausgabe 7/2019

CNS Drugs 7/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.